cnbc_topnews

Oil prices mixed in choppy trade as Trump plans to 'free' ships stranded due to Mideast conflict

oil prices swung monday, with brent crude marginally lower at $101.94 and wti up 0.15% to $108.33. traders were digesting trump's plan to "free" ships trapped in the strait of hormuz, which has seen traffic nearly stop since the iran war began.

the operation, called "project freedom," started monday. us central command said it will involve guided-missile destroyers, over 100 aircraft, unmanned platforms, and 15,000 service members. the focus is on getting civilian ships from non-conflict countries out of the waterway. separately, a tanker was hit by projectiles north of fujairah in the uae, per the uk maritime trade operations agency.

opec+ agreed to increase output by 188,000 barrels per day in its first meeting since the uae left. moody's analytics' gaurav ganguly warned on cnbc that sustained brent above $125 could push the global economy into recession.

source: cnbc_topnews
sentiment: -0.30 · impact: 0.70

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds